Novavax Inc
NVAXNovavax Inc (NVAX) is a biotechnology company specializing in the development and commercialization of innovative vaccines to prevent serious infectious diseases. Founded in 1987, Novavax focuses on nanoparticle technology and adjuvants to create vaccines for influenza, RSV, COVID-19, and other diseases. The company aims to provide safe and effective immunization options through its advanced vaccine platforms.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 31, 2007 | $0.11 | 2007-12-13 | 2007-12-17 |
| November 30, 2007 | $0.11 | 2007-11-13 | 2007-11-15 |
| October 31, 2007 | $0.11 | 2007-10-11 | 2007-10-15 |
| September 28, 2007 | $0.11 | 2007-09-13 | 2007-09-17 |
| August 31, 2007 | $0.11 | 2007-08-13 | 2007-08-15 |
Dividends Summary
- Consistent Payer: Novavax Inc has rewarded shareholders with 6 dividend payments over the past 0 years.
- Total Returned Value: Investors who held NVAX shares during this period received a total of $0.64 per share in dividend income.
- Latest Payout: The most recent dividend of $0.11/share was paid 6774 days ago, on December 31, 2007.
- Yield & Schedule: NVAX currently pays dividends monthly with an annual yield of 7.76%.
- Dividend Growth: Since 2007, the dividend payout has grown by 0.0%, from $0.11 to $0.11.
- Dividend Reliability: NVAX has maintained or increased its dividend for 6 consecutive payments.
Company News
A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demon...
Novavax stock surged 13.16% on Friday, tracking gains in Moderna following the publication of Phase 3 results for Moderna's mRNA-based seasonal flu vaccine in the New England Journal of Medicine. The article also notes Moderna's early-stage hantavirus vaccine research collaboration with the U.S. Army and Korea University. Novavax reported Q1 2025...
Novavax shares surged 28% in 2026 following a licensing deal with Pfizer for its Matrix-M adjuvant technology, worth $30M upfront plus up to $500M in milestones. However, the analyst recommends staying away from the stock due to uncertain core business fundamentals, inconsistent revenue from its coronavirus vaccine franchise, pipeline risks inclu...
ImmunityBio surged 17.39% on January 20, 2026, following FDA end-of-phase discussions that outlined a resubmission path for its ANKTIVA therapy in BCG-unresponsive papillary bladder cancer. The stock has more than doubled in five days, driven by triple-digit revenue growth and expanding indications for its primary therapy, though investors should...
Representative Haley Stevens announced plans to draft articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr., criticizing his healthcare policies and claiming he has caused 'health care chaos' and rising costs.
